Matches in Wikidata for { <http://www.wikidata.org/entity/Q91758625> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q91758625 description "article scientifique publié en 2020" @default.
- Q91758625 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91758625 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91758625 description "scientific article published on 09 April 2020" @default.
- Q91758625 description "wetenschappelijk artikel" @default.
- Q91758625 description "наукова стаття, опублікована 9 квітня 2020" @default.
- Q91758625 name "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 name "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 type Item @default.
- Q91758625 label "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 label "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 prefLabel "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 prefLabel "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 P1433 Q91758625-95745B89-DDB9-4EB1-B0EA-C53A315F502A @default.
- Q91758625 P1476 Q91758625-3333C984-0187-4BEB-B120-B232C1A712A4 @default.
- Q91758625 P2093 Q91758625-13883D81-3ACD-4CD7-969E-DC1B0FA178E8 @default.
- Q91758625 P2093 Q91758625-25A4EB17-6D6B-420A-B642-A2E2880FB511 @default.
- Q91758625 P2093 Q91758625-2962F4A0-C330-4463-96E4-BD4930368F68 @default.
- Q91758625 P2093 Q91758625-3BB80995-EDF8-4663-969B-6DA73C0381CD @default.
- Q91758625 P2093 Q91758625-469551F8-C816-41C1-A8A6-12A276DE7166 @default.
- Q91758625 P2093 Q91758625-47F8979A-E565-458A-BD3C-1878658741BF @default.
- Q91758625 P2093 Q91758625-4E571B0A-F89D-41E4-ABA2-55A57D559452 @default.
- Q91758625 P2093 Q91758625-9AE15901-1788-4E25-AC92-DD76F47FEDB9 @default.
- Q91758625 P2093 Q91758625-A6C451D3-6D32-4751-88E6-D7B8BE50CECA @default.
- Q91758625 P2093 Q91758625-B3A6AE67-62CC-472F-9A2E-F6C3D86969E8 @default.
- Q91758625 P2093 Q91758625-BADE1F3C-3346-4EE7-96D8-E1A6E618EA59 @default.
- Q91758625 P2093 Q91758625-C6508CC4-5A65-4443-806B-72FFDBD49259 @default.
- Q91758625 P2093 Q91758625-CBDDAA6C-1D5C-402B-A06D-5118CDF91595 @default.
- Q91758625 P2093 Q91758625-DF07E780-8C41-4C61-A146-A7FAC3E3BEF8 @default.
- Q91758625 P2093 Q91758625-E94F55A7-8E00-41C4-8418-32DB5873790D @default.
- Q91758625 P31 Q91758625-0E4A7FD3-0A11-4429-9DFA-D9BCFC635683 @default.
- Q91758625 P356 Q91758625-0B06F086-CFB5-46CC-BD13-64C606F2C623 @default.
- Q91758625 P577 Q91758625-5875755C-6783-4E3E-8D84-FDC1218347DC @default.
- Q91758625 P698 Q91758625-82A7D2F8-10BF-4F2B-AEDB-52094593ACAF @default.
- Q91758625 P921 Q91758625-24DB9299-9289-45A0-AF8C-C5CD7F32DC72 @default.
- Q91758625 P921 Q91758625-9BC1A7A3-2B12-4B31-8860-945660B2C6F9 @default.
- Q91758625 P921 Q91758625-BD04C0EE-59BD-4E67-8105-80B34C9B6E97 @default.
- Q91758625 P932 Q91758625-624E42F7-23E6-4638-9071-56F1362B6D30 @default.
- Q91758625 P356 JAMAONCOL.2020.0409 @default.
- Q91758625 P698 32271354 @default.
- Q91758625 P1433 Q22079683 @default.
- Q91758625 P1476 "Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial" @default.
- Q91758625 P2093 "Amir Carmona" @default.
- Q91758625 P2093 "Andrés F Cardona" @default.
- Q91758625 P2093 "Beatriz Mota-Vega" @default.
- Q91758625 P2093 "Christian Rolfo" @default.
- Q91758625 P2093 "Diego Díaz-García" @default.
- Q91758625 P2093 "Feliciano Barrón" @default.
- Q91758625 P2093 "Fernando Aldaco" @default.
- Q91758625 P2093 "Laura Alejandra Ramírez-Tirado" @default.
- Q91758625 P2093 "Marco Polo Peralta Álvarez" @default.
- Q91758625 P2093 "Masao Yamamoto Ramos" @default.
- Q91758625 P2093 "Oscar Arrieta" @default.
- Q91758625 P2093 "Rafael Rosell" @default.
- Q91758625 P2093 "Raquel Gerson" @default.
- Q91758625 P2093 "Yolanda Bautista" @default.
- Q91758625 P2093 "Zyanya Lucia Zatarain-Barrón" @default.
- Q91758625 P31 Q13442814 @default.
- Q91758625 P356 "10.1001/JAMAONCOL.2020.0409" @default.
- Q91758625 P577 "2020-04-09T00:00:00Z" @default.
- Q91758625 P698 "32271354" @default.
- Q91758625 P921 Q13896859 @default.
- Q91758625 P921 Q420436 @default.
- Q91758625 P921 Q42824440 @default.
- Q91758625 P932 "7290397" @default.